masthead-news

News & Events

PROOF for FFPE samples | Drug Discovery News

TUCSON, Ariz.—HTG Molecular Diagnostics and the Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) have finalized a license agreement that provides HTG exclusive rights to commercialize PROOF Centre-developed gene expression blood tests to evaluate the prognosis of chronic obstructive pulmonary disease (COPD) patients who are likely to experience frequent exacerbations known as lung attacks.

Read More

Posted on:
 

Page last updated June 08, 2020